Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Indian Regulator Approves Favipiravir For The Treatment Of Mild To Moderate COVID-19 In India

 We would like to inform you that Glenmark Pharmaceuticals has just received the manufacturing and marketing approval from India's drug regulator to launch the oral antiviral drug Favipiravir (FabiFlu(r)) for the treatment of mild to moderate COVID-19 patients in India. This approval has been granted based on evaluation of data and in consultation with the Subject Expert Committee, as part of accelerated approval process, considering the emergency situation and unmet medical need of the COVID-19 outbreak. It is for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation. We will provide more details shortly. This is for your information and record please.
19-06-2020
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark Pharmaceuticals receives ANDA approval for Fingolimod Capsules, 0.5 mg
19-06-2020
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Enclosed please find herewith the details of Earnings Call slated for Monday, June 29, 2020 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.
17-06-2020
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Board to consider FY20 results & Dividend on June 26, 2020

 Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors will be held on June 26, 2020, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2020 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2020.Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31, 2020 till 48 hours after the declaration of financial results of the Company for the quarter and year ended March 31, 2020.
17-06-2020
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window

 We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, June 26, 2020, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2020 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2020. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31, 2020 till 48 hours after the declaration of financial results of the Company for the quarter and year ended 31st March, 2020.
17-06-2020
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for Audited Financial Results For The Quarter And Year Ended March 31, 2020

 GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/06/2020 ,inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2020 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2020. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31, 2020 till 48 hours after the declaration of financial results of the Company for the quarter and year ended 31st March, 2020.
17-06-2020

Buy Glenmark Pharmaceuticals; target of Rs 410: Globe Capital Market

 Globe Capital Market is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 410 in its research report dated Jun 01, 2020.
02-06-2020

Glenmark gets USFDA nod to market generic drug for muscle pain

 Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for Chlorzoxazone tablets USP, in strength of 375 mg and 750 mg, the drug maker said in a statement.
27-05-2020
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Sub: Glenmark Pharmaceuticals receives ANDA approval for Chlorzoxazone Tablets USP, 375 mg and 750 mg; Glenmark's first ANDA approval out of their new U.S. facility With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.
27-05-2020
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark to commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in hospitalized patients of moderate COVID-19 in India
26-05-2020
Next Page
Close

Let's Open Free Demat Account